ID
21753
Beschrijving
VELCADE®,Rituximab,Cyclophosphamide and Decadron (VRCD Regimen); ODM derived from: https://clinicaltrials.gov/show/NCT00413959
Link
https://clinicaltrials.gov/show/NCT00413959
Trefwoorden
Versies (1)
- 27-04-17 27-04-17 -
Geüploaded op
27 april 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Lymphoma, Non-Hodgkin NCT00413959
Eligibility Lymphoma, Non-Hodgkin NCT00413959
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
HIV Seropositivity
Datatype
boolean
Alias
- UMLS CUI [1]
- C0019699
Beschrijving
Central Nervous System Involvement
Datatype
boolean
Alias
- UMLS CUI [1]
- C4050309
Beschrijving
Therapeutic procedure Lymphoma | MALT Lymphoma Antibiotic therapy Excluded
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C0024299
- UMLS CUI [2,1]
- C0242647
- UMLS CUI [2,2]
- C0338237
- UMLS CUI [2,3]
- C2828389
Similar models
Eligibility Lymphoma, Non-Hodgkin NCT00413959
- StudyEvent: Eligibility
C0432516 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0444956 (UMLS CUI [2,2])
C1512714 (UMLS CUI [2,3])
C1504389 (UMLS CUI [3,1])
C1512714 (UMLS CUI [3,2])
C0024419 (UMLS CUI [2])
C0338237 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
C3826993 (UMLS CUI [3,1])
C0231175 (UMLS CUI [3,2])
C0031843 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
C0024299 (UMLS CUI [1,2])
C0242647 (UMLS CUI [2,1])
C0338237 (UMLS CUI [2,2])
C2828389 (UMLS CUI [2,3])